NCT05410496View on ClinicalTrials.gov

Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients with Chronic HBV Infection

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

June 22, 2021

Primary Completion Date

July 30, 2024

Study Completion Date

July 30, 2027

Conditions
Safety IssuesChronic Hepatitis BTransplant Recipient
Interventions
DRUG

Tenofovir Alafenamide 25 MG

To assess the safety, efficacy, and drug adherence improvement of TAF switching therapy in kidney or liver transplant patients with HBV infection.

Trial Locations (2)

40447

China Medical University Hospital, Taichung

40705

Taichung Veterans General Hospital, Taichung

All Listed Sponsors
collaborator

Institute of Adherence to Medication

UNKNOWN

lead

Taichung Veterans General Hospital

OTHER

NCT05410496 - Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients with Chronic HBV Infection | Biotech Hunter | Biotech Hunter